DDInter336 DDInter629
Celecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, is a nonsteroidal anti-inflammatory drug (NSAID) which is known for its decreased risk of causing gastrointestinal bleeding compared to other NSAIDS. It is used to manage symptoms of various types of arthritis pain and in familial adenomatous polyposis (FAP) to reduce precancerous polyps in the colon. It is marketed by Pfizer under the brand name Celebrex, and was initially granted FDA approval in 1998. Interestingly, selective COX-2 inhibitors (especially celecoxib), have been evaluated as potential cancer chemopreventive and therapeutic drugs in clinical trials for a variety of malignancies.
Eliglustat is a glucosylceramide synthase inhibitor used for the long-term treatment of type 1 Gaucher disease.[A3752,L41404] Gaucher disease is a rare genetic disorder characterized by the deficiency of acid β-glucosidase, an enzyme that converts glucosylceramide into glucose and ceramide. In patients with Gaucher disease, the accumulation of glucosylceramide leads to the formation of Gaucher cells that infiltrate the liver, spleen, bone marrow and other organs. This leads to complications such as anemia and thrombocytopenia.[L41404,A246384] By inhibiting glucosylceramide synthase, eliglustat reduces the accumulation of glucosylceramide. Eliglustat is mainly metabolized by CYP2D6. Patients selected for eliglustat treatment undergo an FDA-cleared genotyping test to establish if they are CYP2D6 extensive metabolizers (EMs), intermediate metabolizers (IMs), or poor metabolizers (PMs). The results of this test dictate eliglustat dosing recommendations for each type of patient. There are no dosing recommendations for CYP2D6 ultra-rapid or indeterminate metabolizers.[L41404,A7634] Eliglustat was approved by the FDA in August 2014 as an oral substrate reduction therapy for the first-line treatment of type 1 Gaucher disease.[L41404,A7634] Enzyme replacement continues to be the standard of care for the treatment of type 1 Gaucher disease ([imiglucerase], [velaglucerase alfa], [taliglucerase alfa]); however, oral substrate reduction therapies with favourable safety profiles, such as eliglustat, represent a treatment alternative.[A246389,A7634]
Celecoxib {u} (Compound) binds {v} (Gene) CYP2D6
CYP2D6 {u} (Gene) is bound by {v} (Compound) Donepezil
Donepezil {u} may cause a minor interaction that can limit clinical effects when taken with {v} Eliglustat
Celecoxib {u} (Compound) binds {v} (Gene) CYP2D6
CYP2D6 {u} (Gene) is bound by {v} (Compound) Trimipramine
Trimipramine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Eliglustat
Celecoxib {u} (Compound) causes {v} (Side Effect) Abdominal pain upper
Abdominal pain upper {u} (Side Effect) is caused by {v} (Compound) Donepezil
Donepezil {u} may cause a minor interaction that can limit clinical effects when taken with {v} Eliglustat
Celecoxib {u} (Compound) causes {v} (Side Effect) Abdominal pain upper
Abdominal pain upper {u} (Side Effect) is caused by {v} (Compound) Epirubicin
Epirubicin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Eliglustat
Celecoxib {u} (Compound) causes {v} (Side Effect) Irritable bowel syndrome
Irritable bowel syndrome {u} (Side Effect) is caused by {v} (Compound) Duloxetine
Duloxetine {u} may lead to a major life threatening interaction when taken with {v} Eliglustat
Celecoxib {u} (Compound) binds {v} (Gene) CYP2C9
CYP2C9 {u} (Gene) is bound by {v} (Compound) Miconazole
Miconazole {u} may lead to a major life threatening interaction when taken with {v} Eliglustat
Celecoxib {u} (Compound) resembles {v} (Compound) Etoricoxib
Etoricoxib {u} (Compound) resembles {v} (Compound) Vemurafenib
Vemurafenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Eliglustat
Celecoxib {u} (Compound) binds {v} (Gene) PTGS2
PTGS2 {u} (Gene) is upregulated by {v} (Compound) Topotecan
Topotecan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Eliglustat
Celecoxib {u} (Compound) binds {v} (Gene) PTGS2
PTGS2 {u} (Gene) is bound by {v} (Compound) and {u} (Gene) is upregulated by {v} (Compound) Etoposide
Etoposide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Eliglustat
Celecoxib {u} (Compound) upregulates {v} (Gene) ST3GAL5
ST3GAL5 {u} (Gene) is upregulated by {v} (Compound) Perphenazine
Perphenazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Eliglustat
Celecoxib (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Donepezil (Compound) and Donepezil may cause a minor interaction that can limit clinical effects when taken with Eliglustat
Celecoxib (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Trimipramine (Compound) and Trimipramine may cause a moderate interaction that could exacerbate diseases when taken with Eliglustat
Celecoxib (Compound) causes Abdominal pain upper (Side Effect) and Abdominal pain upper (Side Effect) is caused by Donepezil (Compound) and Donepezil may cause a minor interaction that can limit clinical effects when taken with Eliglustat
Celecoxib (Compound) causes Abdominal pain upper (Side Effect) and Abdominal pain upper (Side Effect) is caused by Epirubicin (Compound) and Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Eliglustat
Celecoxib (Compound) causes Irritable bowel syndrome (Side Effect) and Irritable bowel syndrome (Side Effect) is caused by Duloxetine (Compound) and Duloxetine may lead to a major life threatening interaction when taken with Eliglustat
Celecoxib (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Miconazole (Compound) and Miconazole may lead to a major life threatening interaction when taken with Eliglustat
Celecoxib (Compound) resembles Etoricoxib (Compound) and Etoricoxib (Compound) resembles Vemurafenib (Compound) and Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Eliglustat
Celecoxib (Compound) binds PTGS2 (Gene) and PTGS2 (Gene) is upregulated by Topotecan (Compound) and Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Eliglustat
Celecoxib (Compound) binds PTGS2 (Gene) and PTGS2 (Gene) is bound by Etoposide (Compound) and PTGS2 (Gene) is upregulated by Etoposide (Compound) and Etoposide may cause a moderate interaction that could exacerbate diseases when taken with Eliglustat
Celecoxib (Compound) upregulates ST3GAL5 (Gene) and ST3GAL5 (Gene) is upregulated by Perphenazine (Compound) and Perphenazine may cause a moderate interaction that could exacerbate diseases when taken with Eliglustat